Ridgefield, CT, April 6, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) filed a supplemental New Drug Application (sNDA) for ...

Pradaxa® (dabigatran etexilate mesylate) U.S. Label Now Affirms Superior Reduction in Ischemic and Hemorrhagic Stroke Versus Warfarin in Patients with Non-Valvular Atrial Fibrillation RIDGEFIELD, Conn ...

RIDGEFIELD, Conn., June 26, 2014 -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ...

Please provide your email address to receive an email when new articles are posted on . Studies on Xeljanz as vitiligo treatment and the continued use of Pradaxa and Xarelto during cutaneous surgery ...

PRADAXA (dabigatran etexilate) 75mg, 150mg capsules by Boehringer Ingelheim This marks the fourth FDA approval for the anticoagulant. The Food and Drug Administration (FDA) has approved Pradaxa ...

RIDGEFIELD, Conn., Nov. 13, 2017 /PRNewswire/ -- Boehringer Ingelheim today announced results from two new analyses of the phase III RE-VERSE AD™ study, which evaluated the safety and efficacy of ...

Ingelheim, Germany – Boehringer Ingelheim wants to set the record straight following misleading statements that the British Medical Journal (BMJ) published today regarding Pradaxa® (dabigatran ...

RIDGEFIELD, Conn., Nov. 10, 2017 /PRNewswire/ -- Boehringer Ingelheim today announced that important sub-analyses from three major trials in anticoagulation care will be presented at the American ...

The Food and Drug Administration (FDA) has grated accelerated approval to Praxbind (idarucizumab; Boehringer Ingelheim) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during ...

Dallas, Nov 18 (Reuters) - An experimental antidote to the widely used blood clot preventer Pradaxa worked immediately and completely in an early-stage trial among healthy volunteers, raising hopes ...